Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Single Dose, Open-label, Two Parts, Two and Three Period Cross-over Study to Investigate the Relative Bioavailability of Two Tablet Formulations and the Effect of Fasting Following Oral Administration of RO4995819 in Healthy Subjects

Next Previous
Search
Trial Profile

A Randomized, Single Dose, Open-label, Two Parts, Two and Three Period Cross-over Study to Investigate the Relative Bioavailability of Two Tablet Formulations and the Effect of Fasting Following Oral Administration of RO4995819 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Sep 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Decoglurant (Primary)
  • Indications Major depressive disorder
  • Focus Pharmacokinetics
  • Sponsors Roche

Most Recent Events

  • 26 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
  • 20 Oct 2014 Planned End Date changed from 1 Mar 2016 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
  • 20 Oct 2014 Planned primary completion date changed from 1 Mar 2016 to 1 Nov 2015 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top